Nicotine cessation: the 12-week structured GP protocol

A structured protocol because nicotine dependence responds to structure

Tobacco and nicotine use is Australia’s leading preventable cause of death, accounting for approximately 21,000 deaths and $136 billion in annual societal costs. About 11% of Australian adults smoke daily; prevalence is substantially higher in Aboriginal and Torres Strait Islander communities (34.1% in 2022–23), people with severe mental illness, and lower-socioeconomic groups.

The RACGP Supporting smoking and vaping cessation guideline (2024 update) consolidates the evidence and the operational framework. This article translates that into a week-by-week general-practice protocol — pharmacotherapy choice, PBS authority codes, Quitline integration, and adaptations for high-prevalence groups.

Nicotine activates α4β2 nicotinic acetylcholine receptors in the ventral tegmental area, driving dopaminergic reward via the nucleus accumbens. Receptor upregulation underlies tolerance. Abrupt cessation produces a predictable withdrawal syndrome — peak at day 2–3, mostly resolving over 2–4 weeks — making pharmacotherapy during that window particularly effective. The 12-week protocol duration aligns with the receptor-downregulation timeline, not an arbitrary calendar.

A. Core clinical — the AU general-practice framework

The 5As brief intervention — at every consultation

The RACGP recommends embedding the 5As at every GP visit for current or recent tobacco users:

• Ask — smoking and vaping status at every visit; document Fagerström score and pack-years.
• Advise — clear, personalised statement: “As your GP, the most important change you can make for your health is to stop smoking.”
• Assess — readiness to quit. If not ready, use the 5Rs motivational framework (Relevance, Risks, Rewards, Roadblocks, Repetition) and revisit at the next visit.
• Assist — offer pharmacotherapy, enrol in Quitline 13 78 48 proactive callback, download myQuitBuddy together in the consultation.
• Arrange — book the Week-2 review before the patient leaves; flag the day-3 craving check call.

For people ambivalent about quitting, motivational framing helps: $40 per day on cigarettes is $14,600 per year; carbon monoxide normalises within 24 hours of quitting; cardiovascular risk halves within 12 months; lung cancer risk halves over 10 years.

Week-by-week protocol schedule

Week 0 — Assessment and scripting (MBS 36 or 44): Complete the Fagerström Test for Nicotine Dependence. Score ≥6 indicates high dependence and guides pharmacotherapy toward varenicline or combination therapy. Assess comorbidities — depression (PHQ-9), anxiety (GAD-7), cardiovascular disease, COPD, pregnancy, epilepsy, and eating disorder all influence prescribing. Set a quit date within two weeks; Monday start dates show slightly better adherence. Prescribe and explain the side-effect profile; refer to Quitline with patient consent; make a pre-quit-date plan (remove cigarettes and lighters, air the car, brief household members).

Week 1 — Quit day and day-3 phone check (practice nurse MBS 10997): Patch applied on waking; short-acting NRT used as needed for cravings; varenicline already titrated to 1 mg twice daily by now if chosen. Day-3 phone check addresses the peak withdrawal window — reinforce the “4Ds” (Delay, Deep breathe, Drink water, Distract). Troubleshoot side effects: NRT skin reaction (rotate patch sites, brief 1% hydrocortisone); varenicline nausea (take with food); varenicline vivid dreams (move evening dose to morning).

Week 2 — In-person review (MBS 23 or 36): Confirm abstinence by self-report — CO breath test if available (< 10 ppm = non-smoker). Most patients under-use short-acting NRT; encourage use hourly if cravings are present, not only at peak craving. Confirm Quitline contact was made. Screen mood and behaviour for TGA label compliance.

Weeks 4 and 8 — Mid-course reviews: Continue pharmacotherapy if tolerated and abstinent. Where one or more slips have occurred, troubleshoot trigger; consider adding short-acting NRT to varenicline rather than abandoning the attempt. Average post-cessation weight gain is 4–5 kg — counsel as an acceptable trade-off, pre-empt with diet plan and exercise referral via GPCCMP if needed.

Week 12 — End of course (MBS 36 or 44): Step-down NRT gradually (21 → 14 → 7 mg over 2–4 weeks; keep short-acting NRT as rescue for 1–3 months). Varenicline: stop, or extend via the PBS further 12-week supply for documented responders with ongoing counselling. Bupropion: cease at week 7–9. Write a relapse-prevention plan — triggers, coping strategies, emergency Quitline access — and review it in the appointment.

Follow-up at 6 and 12 months: Confirm continuous abstinence; document 7-day point-prevalence abstinence in the record. Restart pharmacotherapy immediately on relapse — no waiting period; early resumption improves sustained outcomes.

Pharmacotherapy decision algorithm

Clinical picture	Recommended approach
Low–moderate dependence (FTND < 6, ≤ 20 cigarettes/day)	Combination NRT — 21 mg/24-hour patch plus short-acting lozenge or gum 2–4 mg as needed
High dependence (FTND ≥ 6 or > 20 cigarettes/day) or prior NRT failure	Varenicline 0.5 mg once daily days 1–3 → 0.5 mg twice daily days 4–7 → 1 mg twice daily weeks 2–12 (PBS Authority Streamlined)
Very high dependence (> 29 cigarettes/day) or varenicline monotherapy failure	Combination varenicline plus NRT patch — superior to varenicline alone in heavy smokers
Varenicline not tolerated or eGFR < 30	Bupropion 150 mg once daily × 3 days → 150 mg twice daily × 7–9 weeks (avoid in epilepsy, eating disorder, acute alcohol withdrawal)
Pregnancy	Behavioural support plus intermittent NRT first; lower-dose 15 mg / 16-hour patch if needed; avoid varenicline and bupropion

B. Evidence — efficacy and safety

NRT, varenicline, and combination approaches

Cochrane network meta-analysis (Cahill 2013) established the comparative hierarchy: varenicline monotherapy is approximately 50% more effective than single-product NRT; combination NRT outperforms NRT monotherapy; and the evidence base supports using pharmacotherapy over unaided cessation in all dependence groups.

Koegelenberg et al. (JAMA 2014) randomised 446 heavy smokers to varenicline alone or varenicline plus nicotine patch — the combination arm achieved significantly higher 12-week continuous abstinence (55.4% versus 40.9%). This benefit in very heavy smokers was subsequently confirmed in a 2025 meta-analysis (Zhou, Addiction), which anchors the combination recommendation to the > 20 cigarettes/day threshold.

Background unaided 12-month continuous abstinence sits at 3–5% in population studies. Combination pharmacotherapy with structured behavioural support raises this to 20–30% — a 5–10-fold improvement over willpower alone. Most people require between 5 and 30 quit attempts before sustained abstinence; each attempt refines the approach.

Varenicline neuropsychiatric safety — the EAGLES trial

The EAGLES trial (Anthenelli et al., Lancet 2016) enrolled 8,144 smokers — half with stable psychiatric diagnoses — randomised to varenicline, bupropion, nicotine patch, or placebo. Varenicline showed no excess neuropsychiatric events compared with placebo or patch in either the psychiatric or non-psychiatric cohort. The FDA removed its black-box warning for neuropsychiatric adverse events in 2016. Australian prescribing information retains a requirement to document and monitor mood and behaviour; the week-2 and week-4 reviews systematically satisfy this requirement.

Behavioural support — Quitline evidence

Cochrane meta-analysis (Matkin 2019) demonstrated that proactive multi-session Quitline callback increases cessation by approximately 30% compared with reactive-only contact. Cochrane (Hartmann-Boyce 2021) confirms behavioural support adds independent effect over pharmacotherapy alone. This is why the Week 0 appointment explicitly enrols patients in proactive callback rather than leaving first contact to the patient.

C. Relapse prevention and nicotine vapes

Relapse-prevention framework

The written relapse-prevention plan produced at Week 12 covers four domains:

1. Trigger mapping — emotional (stress, boredom, frustration), social (alcohol, peers who smoke), situational (post-meal, driving, coffee).
2. Substitute behaviours — short walk, cold water, sugarless gum, slow breathing exercises.
3. Cognitive reframing — cravings peak at 3–5 minutes then pass; a slip is information, not a verdict. Research confirms the “one-puff effect” is pharmacologically real (Brandon, J Consult Clin Psychol 2007) — a single slip substantially increases full-relapse risk — so same-day Quitline re-engagement at the first slip is emphasised in the plan.
4. Emergency protocol — Quitline 13 78 48 at the first slip; short-acting NRT as rescue for 6–12 months after the end of the main course.

The plan is not a standalone document — it is reviewed in the Week-12 appointment and again at 6-month follow-up.

Nicotine vapes — second-line status and the October 2024 TGA reforms

Cochrane (Lindson 2024) provides high-certainty evidence that nicotine vapes are superior to NRT for smoking cessation in adults seeking to quit. Despite this, the RACGP and AMA position vapes as second-line in the Australian context, citing incomplete long-term pulmonary safety data, dual-use risk, and the adolescent uptake harms documented before the October 2024 regulatory reforms.

Since 1 October 2024, under the TGA vaping framework:

• Therapeutic vapes at ≤ 20 mg/mL nicotine are available from pharmacies without prescription for adults aged 18 and over.
• Under-18s and higher-strength products still require a GP or nurse-practitioner prescription.
• Vapes are not recommended for non-smokers, adolescents, or during pregnancy.
• They are reserved for adults who have already tried and failed first-line standard pharmacotherapy combined with behavioural support.
• New device and ingredient standards from July 2025 tightened the regulatory floor further.

Where therapeutic vapes are used, the clinical goal is eventual cessation from vaping itself — not sustained dual use alongside cigarettes.

D. Australian operations

Quitline and state services

Quitline 13 78 48 operates nationally, with Quit Victoria leading and contracting ACT, NT, and WA lines; iCanQuit covers NSW; Quit SA covers South Australia; and Make Smoking History covers WA. All share the national number. Proactive multi-session callback is the established clinical approach; a dedicated pregnancy line and Aboriginal-identified counsellor service are available through the same number. The myQuitBuddy app provides day-by-day tracking and craving support between appointments.

PBS authority codes

Varenicline (Champix): PBS Authority Required (Streamlined) — initial 12-week supply; further 12-week extension for documented responders with continuing counselling. Concession holders pay the standard PBS co-payment.

Bupropion (Zyban SR): PBS for smoking cessation; up to 9 weeks per year; Authority Required (Streamlined). Avoid in epilepsy, active eating disorder, abrupt alcohol or benzodiazepine withdrawal, and within 14 days of an MAOI.

NRT: Generally over-the-counter. PBS-subsidised (Authority Required Streamlined) for Aboriginal and Torres Strait Islander people, people living with mental illness, and concession card holders — addressing cost as a barrier in the highest-prevalence groups.

MBS billing

• Consults — MBS 23, 36, or 44 by length; telehealth equivalents where the 12-month existing-relationship rule is met.
• GPCCMP (items 965 / 967) — nicotine dependence qualifies as a chronic condition under the post-July 2025 single-plan framework; embeds allied-health referrals for psychology (CBT, motivational interviewing) and dietitian (post-cessation weight management) at 3-monthly reviews.
• MHCP (items 2715 / 2717) — where comorbid depression or anxiety is present; Better Access psychology (10 sessions/year) delivers CBT-based cessation and mood support.
• Practice nurse — item 10997 for the day-3 craving check call and mid-course reviews.
• ATSI Health Assessment — item 715 embeds the smoking-cessation conversation; PBS NRT subsidy eligibility is established through this assessment.

E. Special populations

Pregnancy

All pregnant people who smoke should receive cessation support at every antenatal visit, per the RACGP guideline. Behavioural support through the Quitline pregnancy service is first-line. Intermittent NRT — lozenge, gum, inhaler, or mouth spray — provides lower and more controllable fetal nicotine exposure than a continuous patch. A 15 mg / 16-hour patch (removed overnight) is reasonable where intermittent NRT is insufficient. Varenicline and bupropion are avoided in pregnancy — safety data are insufficient for both. Nicotine vapes are not recommended in pregnancy. The postpartum relapse rate approaches 60% by 6 months; a warm handoff to community Quitline or child and family health nurse at discharge supports sustained abstinence.

Aboriginal and Torres Strait Islander people

Daily smoking prevalence of 34.1% in Aboriginal and Torres Strait Islander adults (2022–23) — down from approximately 50% before 2010 — remains the leading modifiable contributor to the life-expectancy gap (AIHW). The Tackling Indigenous Smoking program funds 26 regional teams delivering culturally tailored cessation support. PBS NRT subsidy for this population removes cost as a barrier. Family and community-of-care quit attempts are frequently more effective than individual-only approaches. The ATSI Health Assessment (MBS 715) is a structured embedded opportunity to initiate cessation conversations and establish subsidy eligibility.

People with mental illness

Smoking prevalence is two to three times the general rate in severe mental illness. The EAGLES trial established that cessation support is safe in stable psychiatric conditions — deferral on the basis of mental illness alone is not justified. Coordinate with the treating psychiatrist where clozapine or olanzapine is prescribed: smoking induces CYP1A2, so cessation raises plasma levels — dose reduction may be needed within weeks of quitting. An MHCP and Better Access psychology referral extends the support team and addresses mood comorbidity directly.

Pre-surgical and occupational groups

Cessation ≥4 weeks before elective surgery reduces wound dehiscence, respiratory complications, and intensive-care admissions (ANZCA perioperative guidance). A proactive cessation offer 6–8 weeks before any planned procedure is a high-yield general-practice action. For patients with occupational combustion exposure — mining, firefighting, construction — smoking cessation substantially modifies cumulative occupational lung-disease risk, and the context of occupational monitoring provides a recurring clinical touchpoint for cessation support.

When to escalate

Seek specialist input or refer when:

• Concurrent substance dependence — opioid, alcohol, or stimulant use disorder requires coordinated addiction medicine input alongside nicotine cessation.
• Severe psychiatric instability — stabilise the psychiatric condition first, then initiate cessation support; do not defer indefinitely.
• Clozapine or olanzapine with complex dose adjustment — liaise with treating psychiatrist before initiating varenicline in this context.
• Adolescents with high-grade nicotine or vape dependence — refer to youth alcohol and other drug services; NRT is off-label under 18; vapes are not recommended; behavioural support is primary.
• Pregnancy with severe dependence unresponsive to intermittent NRT — obstetric and addiction medicine review for patch dosing and risk–benefit assessment.
• Occupational lung disease contributing significantly to respiratory burden — respiratory medicine for COPD or interstitial disease management in parallel with cessation.

What this article is and is not

This is general health information drawn from the RACGP Supporting smoking and vaping cessation guideline (2024), Therapeutic Guidelines, AMH, NPS MedicineWise, TGA regulatory notices, AIHW, and the cited peer-reviewed trials. It describes a clinical protocol framework — it is not personal medical advice and does not create a doctor–patient relationship. Pharmacotherapy choice, PBS authority, and follow-up timing are determined with your own GP and treating clinicians.

Consumer-friendly resources: HealthDirect — quit smoking, Quitline 13 78 48, and the myQuitBuddy app.

---

Sources cited

1. RACGP — Supporting smoking and vaping cessation guideline (2024 update)
2. Therapeutic Guidelines (eTG) — Addiction / Smoking
3. Australian Medicines Handbook — varenicline, NRT, bupropion monographs
4. NPS RADAR — Varenicline (Champix) Authority Required Streamlined
5. NPS RADAR — Varenicline 12-week PBS extension
6. PBS — Varenicline schedule listing
7. TGA — October 2024 vaping reforms
8. TGA — New vaping product standards July 2025
9. AIHW — Tobacco smoking in Australia
10. AIHW — Anti-tobacco programs for Aboriginal and Torres Strait Islander peoples
11. Tackling Indigenous Smoking program
12. Quit Victoria / Quitline 13 78 48; Aboriginal and Torres Strait Islander Quitline services; iCanQuit NSW; Quit SA; Make Smoking History WA
13. HealthDirect — Quit smoking
14. Anthenelli RM et al — EAGLES neuropsychiatric safety trial. Lancet 2016
15. Cahill K et al — Pharmacological interventions for smoking cessation (Cochrane network meta-analysis). Cochrane 2013
16. Koegelenberg CFN et al — Combination varenicline plus NRT versus varenicline alone. JAMA 2014
17. Lindson N et al — Electronic cigarettes for smoking cessation. Cochrane 2024 (pub8)
18. Hartmann-Boyce J et al — Behavioural interventions for smoking cessation. Cochrane 2021
19. Matkin W et al — Telephone counselling for smoking cessation. Cochrane 2019
20. Brandon TH et al — Preventing relapse after smoking cessation. J Consult Clin Psychol 2007
21. MBS Online — items 23, 36, 44, 715, 965, 967, 2715, 2717, 10997
22. ANZCA — Perioperative care of patients who smoke